Key result
The combination of radiotherapy and concurrent trastuzumab in the adjuvant treatment of breast cancer was associated with a mean absolute LVEF reduction of 4% and a 2.4% rate of symptomatic cardiac toxicity.
Why the study?
Does concurrent trastuzumab and radiotherapy increase acute cardiac toxicity in patients with localized HER2-positive breast cancer?
Cohort (n=41)
No
Does concurrent trastuzumab and radiotherapy increase acute cardiac toxicity in patients with localized HER2-positive breast cancer?
The combination of radiotherapy and concurrent trastuzumab in the adjuvant treatment of breast cancer appears to have an acceptable acute cardiac safety profile.
Supports concurrent trastuzumab-radiotherapy with monitoring in HER2-positive breast cancer; leaves open need for randomized confirmation.
The main toxicity of trastuzumab, is the alteration of cardiac function. The objective of this study is to examine the acute cardiotoxicity of the combination of Radiotherapy (RT) and trastuzumab in the adjuvant treatment of breast cancer.
No takes yet. Share an insight, caveat, or question.
Essâdi et al. (2018) conducted a cohort in Localized breast cancer (n=41). Radiotherapy and Trastuzumab was evaluated on Absolute decrease of Left Ventricular Ejection Fraction (LVEF) after the end of radiotherapy. The combination of radiotherapy and concurrent trastuzumab in the adjuvant treatment of breast cancer was associated with a mean absolute LVEF reduction of 4% and a 2.4% rate of symptomatic cardiac toxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: